CervoMed's stock surged more than 400% after interim data showed significant improvement with a new batch of neflamapimod in treating Dementia with Lewy Bodies. The recent interim readout deserves ...
Shares of Bristol Myers Squibb declined after the company announced that the late-stage ODYSSEY-HCM study evaluating cardiovascular drug Camzyos (mavacamten) failed. The phase III study was evaluating ...
On Thursday, Pliant Therapeutics (NASDAQ:PLRX) stock, currently trading at $3.23, maintained a Buy rating and a $32.00 price target from Stifel analysts following recent developments in the company's ...
Shares of Intellia Therapeutics NTLA were down 22.9% yesterday after it announced an update from the ongoing phase III study, evaluating the investigational in vivo genome-editing candidate, nexiguran ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback